Michael Shan
Impact in
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
- Cancer Research top 10%
- Cancer, Lipids, and Metabolism
Papers in
-
- Pneumonia and Respiratory Infections 2
- Urinary Tract Infections Management 1
-
- Cystic Fibrosis Research Advances 1
- Respiratory and Cough-Related Research 1
- Co-authors
- Josep M. Llovet (2 shared papers)Jordi Bruix (2 shared papers)Chetan Lathia (2 shared papers)Gerold Meinhardt (1 shared paper)Carol E. Peña (2 shared papers)Morris Sherman (1 shared paper)Jean‐Luc Raoul (1 shared paper)Guido Gerken (1 shared paper)
- Journals
- Clinical Infectious Diseases (1 paper)Molecular Cancer Therapeutics (1 paper)Clinical Cardiology (1 paper)Journal of Hepatology (1 paper)Contemporary Clinical Trials (1 paper)
- Partner nations
- United StatesSpainItaly
In The Last Decade
Michael Shan
9 papers receiving 1.3k citations
Michael Shan's Hit Papers
Peers
Comparison fields: 5 of 78
- Hepatology 889
- Cancer Research 250
- Pathology and Forensic Medicine 291
- Epidemiology 521
- Urology 71
Countries citing papers authored by Michael Shan
This map shows the geographic impact of Michael Shan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Shan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Shan more than expected).
Fields of papers citing papers by Michael Shan
This network shows the impact of papers produced by Michael Shan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Shan. The network helps show where Michael Shan may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Shan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial Hit paper breakdown → | 2012 | 656 |
| 2 | Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma Hit paper breakdown → | 2012 | 444 |
| 3 | 1999 | 126 | |
| 4 | 1998 | 50 | |
| 5 | 2007 | 30 | |
| 6 | 1999 | 25 | |
| 7 | 1999 | 25 | |
| 8 | 2001 | 12 | |
| 9 | 2009 | 1 |
About Michael Shan
Michael Shan is a scholar working on Epidemiology, Pulmonary and Respiratory Medicine, Otorhinolaryngology, Hepatology and Cancer Research, having authored 9 papers that have together received 1.4k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Sinusitis and nasal conditions (2 papers), Pneumonia and Respiratory Infections (2 papers), Cancer Genomics and Diagnostics (1 paper), Cystic Fibrosis Research Advances (1 paper), Urinary Tract Infections Management (1 paper), Colorectal Cancer Treatments and Studies (1 paper) and Respiratory and Cough-Related Research (1 paper). The work is most often cited by research in Hepatology (889 citations), Cancer Research (250 citations), Pathology and Forensic Medicine (291 citations), Epidemiology (521 citations) and Urology (71 citations). Michael Shan has collaborated with scholars based in United States, Spain and Italy. Frequent co-authors include Josep M. Llovet, Jordi Bruix, Chetan Lathia, Gerold Meinhardt, Carol E. Peña, Morris Sherman, Jean‐Luc Raoul, Guido Gerken, Armando Santoro and Vincenzo Mazzaferro. Their work appears in journals such as Clinical Infectious Diseases, Molecular Cancer Therapeutics, Clinical Cardiology, Journal of Hepatology and Contemporary Clinical Trials.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.